medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number S1

<< Back Next >>

Ann Hepatol 2011; 10 (S1)

Current indications for the use of albumin in the treatment of cirrhosis

Alves MA

Language: English
References: 42
Page: 15-20
PDF size: 139.66 Kb.


ABSTRACT

The role of proteins in the maintenance of colloid osmotic pressure has been described by Starling since 1896. For many decades, the importance of albumin was associated exclusively to its colloid osmotic function. More recently, other properties of albumin have been demonstrated, such as: carrying different substances, anti-inflammatory activity, preserving capillaries permeability, anti-oxidant role. It is noteworthy that, in decompensated cirrhosis, there is qualitative and quantitative decrease in albumin function. This is why, when we use it, we must have in mind its pharmacological role, as well as its colloid osmotic function. Currently, albumin has three major indications in the treatment of cirrhosis. The first would be in the treatment of tense or refractory ascites, when large-volume paracentesis are accomplished, maily when more than 4-5L of ascites are drained, in order to avoid post-paracentesis dysfunction. The second would be in cases of spontaneous bacterial peritonitis, avoiding renal impairment and increasing survival; it is formally indicated when bilirubin is greater than 4 mg/dL or creatinine is greater than 1 mg/dL. Finally, we understand its use associated to terlipressin seems to be the best treatment strategy for type I hepatorenal syndrome. Hence, its judicial use is of great relevance and benefit in the treatment of these complications of the cirrhotic patient.


REFERENCES

  1. Starling EH. On the Absorption of Fluids from the Connective Tissue Spaces. J Physiol 1896; 19: 312-26.

  2. Levy M. Pathophysiology of ascites formation. In: Epstein M. The kidney in liver disease. 4th. Ed. Philadelphia: Hanley & Belfus; 1996, p. 179-220.

  3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.

  4. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41: 1211-9.

  5. Evans TW. Review article: albumin as a drug: biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002; 16: 6-11.

  6. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, Muravsky V, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555-64.

  7. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz- Bankuti C, Hallström S, Lackner C, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008; 1782: 469-73.

  8. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.

  9. Mattos AA; Machado SB; Balle, VR e Dominguez, VV. Sobrevida de pacientes cirróticos com ascite. GED 1998; 17: 17-21.

  10. Quintero E, Ginés P, Arroyo V, Rimola A, Bory F, Planas R, Bellati G, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1985; 8429: 611-2.

  11. Ginés P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-41.

  12. Salerno F, Badalamenti S, Incerti P, Tempini S, Restelli B, Bruno S, Bellati G, et al. Repeated paracentesis and i.v. albumin infusion to treat ‘tense’ ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987; 5: 102-8.

  13. Titó L, Ginès P, Arroyo V, Planas R, Panés J, Rimola A, Llach J, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990; 98: 146-51.

  14. Cárdenas A, Ginès P, Runyon BA. Is albumin infusion necessary after large volume paracentesis? Liver Int 2009; 29: 636-40.

  15. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.

  16. Wong CL, Holroyd-Leduc J, Thorpe KE, Straus SE. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA 2008; 299: 1166-78.

  17. Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, Torres M, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.

  18. Both CT & Mattos AA. Avaliación dos efeitos da paracentese total em pacientes cirróticos. Publicado na revista GED 1994; 13: 85-93.

  19. Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.

  20. Mattos AA, Coral GP, Menti E, Valiatti F, Kraemer C. Infección bacteriana no paciente cirrótico. Arq Gastroenterol 2003; 40: 11-15.

  21. Coral G, Mattos AA, Damo DF, Viégas AC. Prevalência e Prognóstico da Peritonite Bacteriana Espontânea. Experiência em Pacientes internados em um hospital geral de Porto Alegre, RS, Brasil (1991-2000). Arq Gastroenterol 2002; 39: 158-62.

  22. Coral, GP; Mattos, AA. Renal Impairment after Spontaneous Bacterial Peritonitis: Incidence and Prognosis. Canadian J Gastroenterol 2003; 17: 187-90.

  23. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del- Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.

  24. Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, Navasa M, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-34.

  25. Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56: 597-9.

  26. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Muñoz A, Romero G, Levi D, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009; 29: 415-9.

  27. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.

  28. Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008; 134: 1715-28.

  29. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.

  30. Mattos AA, Machado SB, Balle VR, Dominguez VV. Sobrevida de pacientes cirróticos com ascite. GED 1998; 17: 17-21.

  31. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-76.

  32. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.

  33. Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorrenal syndrome. Semin Liver Dis 2008; 28: 81-95.

  34. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, et al. Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.

  35. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.

  36. Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials. Int J Artif Organs 2009; 32: 133-40.

  37. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-84.

  38. Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, Solá E, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-26.

  39. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505.

  40. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64.

  41. Jalan R, Mookerjee R, Cheshire L, Williams R, Davies N. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol 2007; 46: S95.

  42. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol (2010),doi: 10,1016/ j.jhep.2010.05.004.




2020     |     www.medigraphic.com